LONGEVA.

Melanotan II: adverse events and evidence limits

A two-week subcutaneous Melanotan-II pilot in three healthy men described nausea, somnolence, fatigue and spontaneous erections lasting 1–5 hours. [1]

This small dose-escalation sample cannot establish risk frequencies for another preparation. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
NauseaThree healthy men, subcutaneous Melanotan-II, two-week dose-escalation pilotDescribed; the small sample cannot establish a frequency[1]
SomnolenceThe same participantsDescribed; no frequency given[1]
FatigueThe same participantsDescribed; no frequency given[1]
Spontaneous erections lasting 1–5 hoursThe same participantsDescribed; no frequency given[1]

References

  1. R T Dorr et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study https://doi.org/10.1016/0024-3205(96)00160-9.